Latest News

Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58M.

Nuclera's eProtein™ desktop bioprinter

Nuclera, a biotechnology company accelerating protein expression workflows, has just raised an additional $15.5 million in Series B financing to bring the total to $58M. Nuclera will use the additional investments from Jonathan Milner and Verve Ventures to accelerate the commercial launch of the eProtein™ desktop bioprinter. To date, Nuclera has raised a total of $83.3M from investors including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh. 

With this new round of investment Nuclera will look to further their mission of making biology accessible. Historically, developing proteins has been a time-consuming and complex process – taking weeks, months, or even years for a scientist to obtain the required amount of protein samples. However, Nuclera's eProtein™ bioprinter combines cell-free protein synthesis and digital microfluidics to create a novel technology platform that solves this problem within 24 hours – revolutionizing the fragmented protein expression screening system into a single optimized, end-to-end workflow for drug discovery and general bio-innovation.  

The eProtein™ bioprinter will allow researchers to accelerate discoveries and treatments by delivering on-demand, desktop access. Researchers will soon be able to seamlessly move from protein screening to scaled-up expression on an accelerated time frame in all market segments. “Rapid biomanufacturing for proteins doesn’t exist today,” said Jonathan Milner, founder and former CEO of Abcam, Inc and CEO of Meltwind Advisory. “The ability to screen multiple protein expression profiles and print purified proteins in 24 hours will revolutionize laboratory workflows and make a demonstrable impact in terms of time to publish in academia and drug discovery timelines.  The days of screening a single protein expression profile at a time are coming to an end with this technology.”  

Nuclera is excited to continue their preparation for successful commercial launch and will use the funds to support this work. In the near-term, Nuclera will further expand personnel across key functions in order to accelerate through the pre-commercial phase and bring their innovative technology to market. The company is currently in the process of conducting alpha testing with select, key customers to gather market intelligence and shape the full commercial launch. 

Co-founder and Nuclera CEO Michael Chen said, “We’re delighted by the continued support from our existing investors and to have the opportunity to bring on several new strategic partners with our recent Series B raise.  With their support, we are quickly scaling all functions from R&D through to our Commercial team. I’m thrilled to advance our mission of making proteins accessible and continue on our journey to deliver our game-changing technology to the market.”

Nuclera was advised by leading international law firm, Taylor Wessing LLP. Led by partner Ross McNaughton, this is the latest investment opportunity the firm has supported Nuclera on in strategic growth plans to revolutionize access to biology. 

Want to know more about our mission to change synthetic biology?

Our mission is simple: provide high-quality genes and proteins at your benchtop.

Get in touch